Bridget E. Bunner

Array ( [id] => 18770869 [patent_doc_number] => 20230365671 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => IMPROVED ANTI-oxMIF ANTIBODIES WITH REDUCED AGGREGATION POTENTIAL AND REDUCED HYDROPHOBICITY [patent_app_type] => utility [patent_app_number] => 18/029893 [patent_app_country] => US [patent_app_date] => 2021-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23878 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18029893 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17548154 [patent_doc_number] => 20220119495 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => FIBRONECTIN BASED SCAFFOLD PROTEINS HAVING IMPROVED STABILITY [patent_app_type] => utility [patent_app_number] => 17/489391 [patent_app_country] => US [patent_app_date] => 2021-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26127 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17489391 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18830870 [patent_doc_number] => 20230399395 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-14 [patent_title] => ANTI-IL5 NANOANTIBODY AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/251303 [patent_app_country] => US [patent_app_date] => 2021-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11698 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18251303 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17775066 [patent_doc_number] => 20220241415 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-04 [patent_title] => FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS [patent_app_type] => utility [patent_app_number] => 17/472004 [patent_app_country] => US [patent_app_date] => 2021-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12908 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17472004 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18938215 [patent_doc_number] => 20240033354 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-01 [patent_title] => A BROADLY NEUTRALIZING MOLECULE AGAINST CLOSTRIDIUM DIFFICILE TOXIN B [patent_app_type] => utility [patent_app_number] => 18/043878 [patent_app_country] => US [patent_app_date] => 2021-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21851 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18043878 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18582933 [patent_doc_number] => 20230265190 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => ALLOREACTIVE IMMUNE CELL-DISTANCING DEVICE AND USES THEREOF FOR PROTECTING DONOR-DERIVED CELLS FROM ALLOREJECTION [patent_app_type] => utility [patent_app_number] => 18/020500 [patent_app_country] => US [patent_app_date] => 2021-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30175 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 140 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18020500 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17414061 [patent_doc_number] => 20220048965 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-17 [patent_title] => INTERLEUKIN-4 RECEPTOR-BINDING FUSION PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/397287 [patent_app_country] => US [patent_app_date] => 2021-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16995 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17397287 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17383998 [patent_doc_number] => 20220031850 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist For Treatment Of Colorectal Cancer [patent_app_type] => utility [patent_app_number] => 17/397447 [patent_app_country] => US [patent_app_date] => 2021-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60394 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17397447 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17383889 [patent_doc_number] => 20220031741 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => METHODS AND REAGENTS FOR MODULATING MACROPHAGE PHENOTYPE [patent_app_type] => utility [patent_app_number] => 17/396792 [patent_app_country] => US [patent_app_date] => 2021-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11516 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17396792 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17398224 [patent_doc_number] => 20220040314 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => Novel Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist [patent_app_type] => utility [patent_app_number] => 17/396351 [patent_app_country] => US [patent_app_date] => 2021-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 65112 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17396351 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19608907 [patent_doc_number] => 12157773 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-03 [patent_title] => IL27RAlpha binding molecules and methods of use [patent_app_type] => utility [patent_app_number] => 18/006370 [patent_app_country] => US [patent_app_date] => 2021-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24960 [patent_no_of_claims] => 53 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 894 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18006370 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18675106 [patent_doc_number] => 20230312684 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => NEUROPILIN AND ANGIOTENSIN CONVERTING ENZYME 2 FUSION PEPTIDES FOR TREATING VIRAL INFECTIONS [patent_app_type] => utility [patent_app_number] => 18/040083 [patent_app_country] => US [patent_app_date] => 2021-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47532 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -77 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18040083 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19345233 [patent_doc_number] => 20240254196 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => HETERODIMERIC FC FUSION PROTEIN, AND COMPOSITION, USE, AND METHOD RELATED TO SAME [patent_app_type] => utility [patent_app_number] => 18/102438 [patent_app_country] => US [patent_app_date] => 2021-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13945 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18102438 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17556283 [patent_doc_number] => 11312966 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-26 [patent_title] => Nucleic acid for treating mite allergy [patent_app_type] => utility [patent_app_number] => 17/377297 [patent_app_country] => US [patent_app_date] => 2021-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 13737 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17377297 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17460323 [patent_doc_number] => 20220073628 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-10 [patent_title] => ANTI-IL-36R ANTIBODIES FOR THE TREATMENT OF NEUTROPHILIC DERMATOSES [patent_app_type] => utility [patent_app_number] => 17/376233 [patent_app_country] => US [patent_app_date] => 2021-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11847 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17376233 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19327004 [patent_doc_number] => 12044681 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-23 [patent_title] => Protein signatures for distinguishing between bacterial and viral infections [patent_app_type] => utility [patent_app_number] => 17/372575 [patent_app_country] => US [patent_app_date] => 2021-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 36 [patent_no_of_words] => 45555 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17372575 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18550773 [patent_doc_number] => 20230248773 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-10 [patent_title] => Extracellular Vesicles and Compositions Thereof [patent_app_type] => utility [patent_app_number] => 18/014288 [patent_app_country] => US [patent_app_date] => 2021-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12822 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18014288 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17168880 [patent_doc_number] => 20210322550 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-21 [patent_title] => ANTIBODY-CONTAINING FORMULATIONS [patent_app_type] => utility [patent_app_number] => 17/346421 [patent_app_country] => US [patent_app_date] => 2021-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23005 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17346421 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18597251 [patent_doc_number] => 20230272045 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => IL-1 RECEPTOR ANTAGONIST (IL-1 RA) FUSION PROTEINS BINDING TO THE EXTRACELLULAR MATRIX [patent_app_type] => utility [patent_app_number] => 18/001480 [patent_app_country] => US [patent_app_date] => 2021-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31100 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18001480 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18497397 [patent_doc_number] => 20230220027 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-13 [patent_title] => GROWTH FACTOR COMPOSITION FOR CELL CULTURE-PRODUCED MEAT [patent_app_type] => utility [patent_app_number] => 18/000724 [patent_app_country] => US [patent_app_date] => 2021-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10883 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18000724 [rel_patent_id] =>[rel_patent_doc_number] =>)